NEONATAL JAUNDICE – A RARE FORM OF CYSTIC FIBROSIS
Abstract
Background. Cystic fibrosis is an autosomal recessive disorder that results in damage to organs containing secretory epithelial cells. It predominantly affects respiratory tract and pancreatic function. While hepatobiliary system is frequently affected in older children with cystic fibrosis, in neonatal period jaundice caused by cystic fibrosis is a rare condition. Two cases were identified in the last ten years (1988–98) in the Department of Pediatrics University Medical Centre Ljubljana.
Patients and methods. We present two patients with neonatal jaundice as one of the rare features of cystic fibrosis. Laboratory evidences of cholestasis and liver involvement were present in both cases. In the first case, an improvement of a liver disease occured spontaneously and in the second case the resolution of clinical and laboratory evidence of liver disease followed after she had been treated with ursodeoxycholic acid.
Conclusions. Neonatal jaundice and cholestasis can be caused by cystic fibrosis. The treatment is conservative with ursodeoxycholic acid. Only in the cases when the disease is not improving conservatively, the surgical procedure can be considered.
Downloads
References
Roy CC, Silverman A, Algille D eds. Pediatric gastroenterology. 4th ed. London: Mosby, 1995: 963–72.
Kopelman H. Cystic fibrosis. In: Wyllie R, Hyams JS. Pediatric gastrointestinal disease. Philadelphia: Saunders Company, 1995: 854–935.
Gracey M, Anderson CM. Cystic fibrosis: gastrointestinal and nutritional aspects. In: Gracey M, Burke V eds. Pediatric gastroenterology and hepatology. 3rd ed. Boston: Blackwell Scientific Publications, 1993: 531–50.
Boat TF. Cystic fibrosis. In: Nelson WE, Behrman RE, Kliegman RM, Arvin AM. Textbook of pediatrics. 15th ed. Philadelphia: Saunders Company, 1996: 1239–50.
Mowat AP. Liver disorders in childhood. London: Butterworth, 1987.
Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis. Possible relation to focal biliary cirrhosis. J Pediatr 1975; 86: 683–9.
Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child 1995; 72: 281–4.
Shwarz HP, Kraemer R, Thurnheer U et al. Liver involvement in cystic fibrosis. Helv Pediatr Acta 1978; 33: 351–64.
Psacharoupulus HT, Portmann B, Howard ER, Mowat AP. Hepatic complications of cystic fibrosis. The Lancet 1981; ii: 78–80.
Gasken KJ. Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med 1988; 33: 340–6.
Tyson KRT, Schuster SR, Schwachman H. Portal hypertension in cystic fibrosis. J Ped Surg 1986; 3: 271–7.
Gatzimos CD, Jowitt RH. Jaundice in Mucoviscidosis. Am J Dis Child 1955; 89: 182–6.
Valman HB, France NE, Wallis PG. Prolonged neonatal jaundice in cystic fibrosis. Arch Dis Child 1971; 46: 805–7.
Taylor WF, Boulos YQ. Neonatal jaundice associated with cystic fibrosis. Amer J Dis Child 1972; 128: 161–2.
Rosenstein BJ, Oppenheimer EH. Prolonged obstructive jaundice and giant cell hepatitis in an infant with cystic fibrosis. J Pediatr 1977; 91: 1022–3.
Perkins WG, Klein GL, Beckerman GC. Cystic fibrosis mistaken for idiopathic biliary atresia. Clin Pediatr 1985; 24: 107–9.
Festen C, Kuyper F, Holland R, van Haelst U. Neonatal jaundice in cystic fibrosis: A conservative approach is not always justified. Z Kinderchir 1988; 43: 106–7.
Furuya KN, Roberts EA, Canny GJ et al. Neonatal hepatitis syndrome with paucity of interlobular bile ducts in cystic fibrosis. J Ped Gastr Nutr 1991; 12: 127–30.
Evans JS, George DE, Mollit D. Biliary infusion therapy in the insipissated bile syndrome of cystic fibrosis. J Ped Gastr Nutr 1991; 12: 131–5.
Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996; 75: 67–70.
Greenholz SK, Krishnadasan B, Marr C, Cannon R. Biliary obstruction in infants with cystic fibrosis requiring Kasai portoenterostomy. J Pediatr Surg 1997; 23: 175–80.
Scher H, Bishop WP, McCray P. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis. Ann Pharmacother 1997; 31: 1003–5.
Cohn JA. Localization of the CFTR in human bile duct epithelial cells. Gut 1993; 105: 1857–64.
Galabert C, Montet JC, Lengrand D et al. Effects of UDHA on liver function in patients with CF and chronic cholestasis. J Ped 1992; 121: 138–41.
Colombo C, Setchell KDR, Podda M et al. Effects of UDHA therapy for liver disease associated with CF. J Pediatr 1990; 117: 482–9.
Colombo C, Battezzati PM. UDHA for liver disease associated with CF: a double blind multicenter trial. Hepathology 1996; 23: 1484–90.
Colombo C, Crosignani A. UDHA therapy in CF associated liver disease: a dose response study. Hepathology 1992; 16: 924–30.
Lepage G, Paradis K. UDHA improves the hepatic metabolism of essential fatty acids and retinol in children with CF. J Pediatr 1997; 130: 52–8.
Cotting J, Lentze MJ, Reichen J. Effects of UDHA treatment on nutrition and liver function in patients with CF and longstanding cholestasis. Gut 1990; 31: 918–21.
Lindblad A. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosisassociated liver disease. Hepatology 1998; 27: 166–74.
Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000; 108: 481–6.
Ohhama Y. Early prediction of long-term survival and the timing of liver transplantation after the Kasai operation. J Pediatr Surg 2000; 35: 1031–4.
Lang T. Biliary atresia: which factors predict the success of a Kasai operation? An analysis of 36 patients. Eur J Med Res 2000; 5: 110–4.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
